Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
暂无分享,去创建一个
[1] D. Schmolze,et al. Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer: A Systematic Analysis. , 2020, Archives of Pathology & Laboratory Medicine.
[2] R. Dikshit,et al. HER2 borderline is a negative prognostic factor for primary malignant breast cancer , 2020, Breast Cancer Research and Treatment.
[3] D. Sirohi,et al. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory. , 2019, American journal of clinical pathology.
[4] R. Kumar,et al. FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma. , 2019, Indian journal of cancer.
[5] Yi Su,et al. A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry. , 2017, Oncotarget.
[6] G. Bethune,et al. Well‐differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in‐situ hybridization testing? , 2017, Histopathology.
[7] Q. Jamal,et al. Correlation of Hormone Receptor and HER2/neu Expression with Clinicopathologic Parameters in Primary Breast Tumors. , 2016, Asian Pacific journal of cancer prevention : APJCP.
[8] D. Dabbs,et al. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics. , 2011, American journal of clinical pathology.
[9] Sudeep Gupta,et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India. , 2010, The Indian journal of medical research.
[10] J. Cuzick,et al. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer , 2009, Breast Cancer Research.
[11] H. Nisenbaum,et al. HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.
[12] Gaëtan MacGrogan,et al. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations , 2009, Modern Pathology.
[13] A. Plastiras,et al. Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma , 2008, Acta histochemica et cytochemica.
[14] Mehrdad Nadji,et al. HER2 in well differentiated breast cancer: is testing necessary? , 2008, Breast Cancer Research and Treatment.
[15] F. Penault-Llorca,et al. Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification , 2007, Breast Cancer Research.
[16] P. Klein,et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. , 2006, Clinical breast cancer.
[17] Helena R. Chang,et al. Histopathologic Characteristics Predicting HER‐2/neu Amplification in Breast Cancer , 2005, The breast journal.
[18] T. Stephenson,et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques , 2005, Journal of Clinical Pathology.
[19] P. Lal,et al. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. , 2005, American journal of clinical pathology.
[20] M. Gnant,et al. Do we need HER‐2/neu testing for all patients with primary breast carcinoma? , 2003, Cancer.
[21] A. Vincent-Salomon,et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer , 2003, British Journal of Cancer.
[22] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[23] J. Myles,et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. , 2002, American journal of clinical pathology.
[24] Rochelle L. Garcia,et al. C‐ERBB‐2 oncogens protein in In situ and invasive lobular breast neoplasia , 1991 .
[25] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[26] M. Karimlou,et al. Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[27] A. Shamshiri,et al. Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002- 2011. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[28] Y. Yarden,et al. The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] M. J. van de Vijver. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). , 2001, European journal of cancer.